Vonova develops a minimally invasive neurovascular system that leverages the body's venous system to access the brain. This Cerebro Platform allows for targeted delivery of diagnostics and therapeutics without requiring invasive skull drilling. The technology aims to improve treatment options for chronic neurological disorders while reducing patient risk and recovery time.
Funding
Funding not disclosed
Founders
Product
Problem
Many patients with drug-resistant neurological disorders lack access to effective therapies due to the risks associated with traditional methods of accessing the brain, which often involve drilling through the skull. These invasive procedures can lead to complications and limit the number of patients who can benefit from advanced neurological interventions.
Solution
Vonova New Hope is developing a patented endovascular platform that provides a minimally invasive alternative for accessing the brain surface. Their technology utilizes the body's natural venous pathways, allowing access to the brain from a vein near the arm, thereby avoiding the need for skull drilling. This approach enables safe recording and stimulation of neural activity, offering a less risky method for delivering therapies to the brain for patients with drug-resistant neurological disorders. The "Atlas Device" component of the platform expands to cover the brain region of interest and provides high spatial resolution capable of identifying the origin of seizures.
Target Audience
The primary target audience includes patients with drug-resistant neurological disorders who require access to advanced therapies, as well as neurosurgeons and neurologists seeking less invasive methods for brain access and intervention.
Features
- Patented endovascular platform for accessing the brain surface via venous pathways.
- Minimally invasive approach eliminates the need for skull drilling.
- Enables safe recording and stimulation of neural activity.
- "Atlas Device" provides high spatial resolution for identifying the origin of seizures.